Cite
HARVARD Citation
Saab, S. et al. (2014). Cost‐effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Alimentary pharmacology & therapeutics. 40 (6), pp. 657-675. [Online].